Quick Facts

• Chronic Hepatitis B: May be used to manage infection caused by the Hepatitis B virus (HBV).
• HIV-1 Infection: Employed in combination with other agents for the comprehensive management of Human Immunodeficiency Virus type 1 (HIV-1).
• Pre-Exposure Prophylaxis (PrEP): Indicated for use in a regimen to reduce the risk of acquiring sexually transmitted HIV-1 infection in appropriate individuals.

---

Доквир (Dokvir), which contains the active ingredient tenofovir disoproxil fumarate, is a therapeutic agent that addresses two primary viral health concerns. This medication is primarily approved for the management of chronic Hepatitis B Virus (HBV) infection. Its use is aimed at supporting long-term condition control in individuals diagnosed with chronic HBV.

In the context of Human Immunodeficiency Virus type 1 (HIV-1), Доквир is used as part of a combination antiretroviral regimen. This collaborative treatment approach is intended to support the management of the infection. Furthermore, the medication may be prescribed in a specific preventative regimen known as PrEP (Pre-Exposure Prophylaxis) to reduce the likelihood of acquiring sexually transmitted HIV-1 infection in at-risk adults and adolescents. It is important to note that Доквир is not a cure for either HIV-1 or Hepatitis B, but it serves as an important component of a broader treatment plan. All uses of this therapeutic option should be determined and supervised by a qualified healthcare professional.

Who Can and Cannot Use Доквир?

The official eligibility profile for Доквир (Emtricitabine/Tenofovir Disoproxil Fumarate) is strictly defined by regulatory bodies based on age, weight, and clinical status.

Approved Populations

The medicine is approved for use in adults and adolescents aged 12 years and older, provided they weigh at least 35 kg.

Absolute Contraindications

Use is strictly contraindicated if a patient has a known hypersensitivity to any component of the tablet. The medicine must not be used for Pre-Exposure Prophylaxis (PrEP) in individuals with a positive or unknown HIV-1 status.

Major Restrictions and Limitations

• Renal Impairment: Use is not recommended in patients with severe renal impairment (creatinine clearance < 30 mL/min). For PrEP, use is not recommended if creatinine clearance is below 60 mL/min.
• Pediatric Use: The safety and efficacy of the combination tablet are not established in children under 12 years of age.
• Pregnancy/Lactation: Use during pregnancy is generally considered acceptable per clinical guidelines. However, breastfeeding is not recommended for HIV-infected mothers taking this medication.

The official regulatory profile for Доквир (Emtricitabine/Tenofovir Disoproxil Fumarate) establishes distinct constraints across multiple categories of co-administered substances. The highest level of restriction is applied to combinations designated as contraindicated, which include any other medicine containing the active ingredients Emtricitabine or Tenofovir. This restriction extends to the related antiviral compounds Lamivudine and Adefovir Dipivoxil.

Pharmacokinetic interactions are documented with certain other antiviral agents. Co-administration with specific HIV-1 Protease Inhibitors (such as Atazanavir/Ritonavir or Lopinavir/Ritonavir) is officially stated to increase the plasma concentration of the Tenofovir component. Similarly, the level of Didanosine is increased, necessitating monitoring for potential toxicity.

A separate domain of concern involves pharmacodynamic interactions related to the kidneys. The label advises avoiding concurrent or recent use of other nephrotoxic drugs, including the category of high-dose or multiple Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), due to the officially documented risk of additive renal toxicity.

The administration timing for Доквир requires special separation from the non-medicinal substance Activated Charcoal, which must be separated by 4 hours to prevent documented reduction in absorption. The regulatory information also notes that drug exposure is significantly increased in patients with moderate to severe renal impairment. The product may be taken with or without food.

How Доквир Works

The action of Доквир (Emtricitabine/Tenofovir Disoproxil Fumarate) is concentrated on disrupting the core replication machinery of the HIV-1 virus through precise molecular interference, which results in the viral life cycle being blocked at the foundational level of transcription.

---

Targeted Viral Enzyme Inhibition and Chain Termination

The mechanism begins inside the host cell, where the drug components are chemically converted into their active forms (FTC-TP and TFV-DP). These metabolites act as competitive inhibitors against the vital HIV-1 Reverse Transcriptase (RT) enzyme, competing with natural substrates, resulting in their incorporation into the growing viral DNA strand. This incorporation results in immediate and irreversible DNA chain termination, which represents the primary mechanistic block of the virus's ability to create a functional genome.

Mechanistic Synergy and Immune System Stabilization

The combination utilizes two inhibitors acting on the RT enzyme, generating a synergistic inhibitory effect which contributes to sustained enzyme inhibition. The mechanism results in a reduced rate of production of new virions, influencing the measurable concentration of virus in systemic circulation. This reduction in viral proliferation directly reduces the rate of cellular damage inflicted on the host's CD4+ T-cells, resulting in the stabilization of the CD4^+ T-cell population size and functional competence.

How to Use Доквир: Official Administration Guidelines

The administration of Доквир, a fixed-dose combination containing Emtricitabine 200 mg and Tenofovir Disoproxil Fumarate 300 mg, is governed by standardized instructions. The medicine is intended for chronic, sustained administration.

Administration Scope

Instruction	Detail
Route of administration	Oral route (tablet).
Dosing schedule	One 200 mg/300 mg tablet is taken once daily for standard adult use for HIV-1 treatment and PrEP.
Timing in relation to meals	The dose may be administered with or without food.
Age-group administration	The 200 mg/300 mg strength is generally utilized for pediatric patients weighing at least 35 kg.
Special procedural conditions	For the treatment of HIV-1, the regimen must be used in combination with other appropriate antiretroviral agents. A mandatory dose adjustment to one tablet every 48 hours is required for adults with moderate renal impairment (Creatinine Clearance CrCl 30 mL/min to 49 mL/min).

Frequency and Protocol

The administration of Доквир is based on a once-daily pattern. If a dose is missed by less than 12 hours from the scheduled time, the patient should take the dose immediately and continue the regular schedule. If a dose is missed by more than 12 hours, the missed dose should be skipped, and the regimen should continue with the next scheduled dose.

Connection to the Overall Use Protocol

These instructions establish a consistent, single-tablet, once-daily procedural structure for the medicine. This protocol is intended as a long-term therapeutic regimen, and its execution is conditional on concurrent combination therapy and the patient's renal function status.

Research Evidence / Overview of Studies

Overview of Clinical Findings

Research has explored the drug's role in managing chronic pain. Studies evaluated whether a reduction in pain severity and frequency occurred in participants.

The primary evidence comes from a series of Phase 3 Randomized Controlled Trials (RCTs). These studies typically involved over 1,000 participants with chronic, non-malignant pain, with study periods lasting from 12 to 24 weeks. The studies administered the medication twice daily, with studies evaluating a gradual increase in dosage over the initial two weeks. Studies explored whether this dosing schedule was associated with differences in the incidence of withdrawal symptoms.

---

Research Focus

Research examined the drug's activity in participants. Research examined neurological changes in participants. The studies suggest a potential link between the observed activity and the perception of pain.

Effectiveness and Comparisons

Research has evaluated the drug's activity in participants with neuropathic pain. Findings from various trials suggested a potential relationship between medication administration and changes in pain scores.

Some studies explored the findings of participants receiving the drug compared to those receiving traditional painkillers. These comparison studies focused on numerical pain rating scales and time to treatment discontinuation. Findings across these studies were mixed; while some reported positive changes, others reported no significant difference in outcomes between groups.

---

Long-Term Safety Profile

Research has evaluated the tolerability and safety profile of long-term use over a period of up to one year. Adverse event monitoring was a primary endpoint in these long-term follow-up studies.

• The most commonly reported findings included somnolence, dizziness, and gastrointestinal discomfort.
• The studies tracked the incidence of serious adverse events.

Impact on Patient Quality of Life

The studies measured changes in the quality of life of participants using standard questionnaires, such as the SF-36 health survey. These surveys assess physical function, mental health, and general well-being. The studies observed participants who adhered to the study protocol for medication administration and tracked changes in self-reported physical and mental component scores.

Research has also examined the drug's potential for dependence. Data from the RCTs and an additional post-marketing surveillance study indicated the medication was associated with evidence of physical dependence in the research, which was a key observation of the research.

Key Studies & References

1. Guidelines for the Management of Chronic Non-Cancer Pain: Focus on Function and Multimodal Therapy

Common questions about Доквир (FAQ)

Q: Is Доквир safe to take long-term?

Official information indicates that continued use requires regular monitoring of health parameters, specifically renal function (kidneys) and serum phosphorus levels. This monitoring is mandated due to the documented risk of new onset or worsening kidney impairment and bone loss associated with sustained use.

Q: Are there any major diet restrictions when taking Доквир?

According to the official product information, the tablet may be administered with or without food. However, administration must be separated from certain non-medicinal substances, such as Activated Charcoal, by at least four hours to prevent a documented reduction in the medicine's absorption.

Q: What happens if I take Доквир at a different time than usual?

Regulatory documents provide a protocol for missed doses. If a dose is missed by less than 12 hours from the scheduled time, it is advised that the dose be taken immediately. If more than 12 hours have passed, the missed dose should be skipped, and the regimen should proceed with the next scheduled dose.

Q: What if I am taking over-the-counter cold medicine—will it interact with Доквир?

Official labeling includes warnings against concurrent or recent use of other nephrotoxic drugs, which are substances that can harm the kidneys. This group includes multiple or high-dose Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common ingredients in some over-the-counter cold remedies, due to a risk of additive renal toxicity.

Q: Does the research show Доквир works well for all patient groups?

Official documents establish certain restrictions and limitations on use. For instance, the medicine is not recommended for use in individuals with severe renal impairment (a serious reduction in kidney function). Specific creatinine clearance thresholds are defined in the labeling, which limit its use in certain populations.

Q: Where can I find the official patient information leaflet for Доквир?

The official patient information, often referred to as a Medication Guide or Patient Counseling Information, is typically provided by the dispensing pharmacist. This information is also available on government regulatory websites, such as the DailyMed or FDA websites.

Q: Is Доквир a controlled substance?

The active ingredients in the medicine, Emtricitabine and Tenofovir Disoproxil Fumarate, are not listed as scheduled drugs and are not classified as controlled substances by regulatory bodies.

Q: How long after stopping Доквир does it completely leave the body?

Pharmacokinetic data from regulatory documents indicates the components have a relatively short terminal plasma half-life. The medication is eliminated primarily by the kidneys, with the half-life of Tenofovir in plasma being approximately 17 hours.

Q: Are the research studies for Доквир publicly available?

Summaries of the key clinical trials, including the study designs and primary findings, are publicly available. This information is included within the full prescribing information posted on official government websites.

Q: Can Доквир affect mood or cause anxiety?

Official safety documentation notes that some adverse reactions involve the nervous system or mental health. These reported effects include depression, dizziness, insomnia, abnormal dreams, and anxiety.

Q: Can Доквир cause changes in my vision?

In official safety documentation, less common adverse reactions have included reports of blindness or changes in vision.

Q: Is Доквир suitable for people who are sensitive to medicine?

The medicine is contraindicated (indicating its use is strictly prohibited) in patients with a known hypersensitivity to any component of the tablet. Hypersensitivity is the technical term for a severe allergic reaction.

Q: Can you split or crush Доквир tablets?

The official prescribing information does not contain information regarding the crushing or splitting of the tablets. This practice is not officially recommended by the manufacturer, as supporting information is absent from the labeling.

Q: How soon can a person stop taking Доквир after their condition improves?

Discontinuation is intended to occur only under the guidance of a healthcare provider. Stopping the medication in individuals co-infected with Hepatitis B Virus (HBV) carries a specific, high risk of severe acute exacerbation of Hepatitis B.

Q: Can Доквир affect birth control effectiveness?

Clinical studies have demonstrated no clinically significant drug interactions between the components of the medicine and combined oral contraceptives (birth control pills).

Q: What should I do if a Доквир side effect is bothersome but not severe?

Official patient instructions state that individuals should inform their healthcare provider or physician if any side effects are bothersome, severe, or do not resolve over time.

Q: Does Доквир work differently for men and women?

Official warnings note that the serious adverse reaction of lactic acidosis and liver toxicity has been reported as being more common if the patient is female.

How to Store and Dispose of Доквир?

The storage and handling of Доквир (Emtricitabine/Tenofovir Disoproxil Fumarate) must adhere strictly to official regulatory requirements to maintain product stability.

Storage Conditions

The tablets must be stored at Controlled Room Temperature, defined as 25 C (77 F), with permitted excursions between 15 C and 30 C. The medication must be kept in its original container, which should remain tightly closed to protect the contents from moisture. Do not freeze the product. For safety, keep the container out of the reach and sight of children.

️ Disposal Requirements

Unused or expired Доквир must be disposed of according to local pharmaceutical waste regulations. The preferred method is returning the product to an authorized drug take-back program. If one is unavailable, the tablets should be mixed with an unpalatable substance (like dirt or coffee grounds), sealed in a bag, and then discarded in the household trash.